5:39 PM
 | 
Apr 30, 2013
 |  BC Extra  |  Financial News

Vertex ups Kalydeco guidance

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) reported 1Q13 financial results after market close on Tuesday and raised its 2013 guidance for net revenues of cystic fibrosis (CF) drug Kalydeco ivacaftor to $300-$340 million...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >